Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Altimmune Inc (ALT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Altimmune's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
7.26 +0.06    +0.83%
27/04 - Closed. Currency in USD ( Disclaimer )
After Hours
7.27
0.01
0.14%
9:25:26 - Real-time Data
  • Volume: 2,232,138
  • Bid/Ask: 7.15 / 7.27
  • Day's Range: 6.90 - 7.42
Type:  Equity
Market:  United States
Altimmune 7.26 +0.06 +0.83%

Altimmune Inc Company Profile

 
Get an in-depth profile of Altimmune Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

52

Equity Type

ORD

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Contact Information

Address 910 Clopper Road Suite 201S
Gaithersburg, 20878
United States
Phone 240 654 1450
Fax -

Top Executives

Name Age Since Title
Wayne F. Pisano 66 2018 Independent Director
David J. Drutz 82 2011 Independent Director
Mitchel B. Sayare 73 2010 Independent Chairman
Philip L. Hodges 52 2017 Independent Director
Vipin K. Garg 63 2018 President, CEO & Director
Klaus O. Schafer 74 2017 Independent Director
Diane Kathryn Jorkasky 72 2020 Independent Director
John M. Gill 72 2004 Independent Director
Caroline M. Apovian - 2022 Member of Obesity Scientific Advisory Board
Louis J. Aronne 68 2022 Member of Obesity Scientific Advisory Board
Robert F. Kushner - 2022 Member of Obesity Scientific Advisory Board
Donna Ryan - 2022 Member of Obesity Scientific Advisory Board
Juan Pablo Frias - 2022 Member of Obesity Scientific Advisory Board
Daniel Joshua Drucker - 2022 Member of Obesity Scientific Advisory Board
Samuel Klein - 2022 Member of Obesity Scientific Advisory Board
Catherine Angell Sohn 71 2023 Independent Director
Lee M. Kaplan - 2023 Member of Obesity Scientific Advisory Board
Rohit Loomba - 2022 Member of Mash Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ALT Comments

Write your thoughts about Altimmune Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email